StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright lowered their price target on shares of Aethlon Medical from $23.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, March 4th.
View Our Latest Stock Analysis on AEMD
Aethlon Medical Stock Performance
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- Election Stocks: How Elections Affect the Stock Market
- What is a Short Call Butterfly Spread? Explanation with Examples
- What is a SEC Filing?
- First Quarter Wrap-Up Reveals Retail’s Shifting Sands
- About the Markup Calculator
- Williams-Sonoma Stock Forecast to Hit $500? Here’s How
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
